GLP-1 / metabolic
Cagrilintide
In clinical trialsAM833 (CagriSema with semaglutide) · Long-acting amylin analog
Weekly amylin analog, paired with semaglutide for added weight loss.
What it is
A long-acting analog of the pancreatic hormone amylin, developed mainly as a partner to semaglutide (CagriSema).
How it works
Agonizes amylin/calcitonin receptors to promote satiety, slow gastric emptying and reduce food intake — complementary to GLP-1.
Studied for
Obesity and T2D weight management, especially as CagriSema.
Regulatory status
Investigational (CagriSema under FDA review).
Safety
Mainly GI (nausea, vomiting); full profile under regulatory review.
What the community reports about Cagrilintide
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The amylin lever. Cagrilintide drives satiety through the amylin receptor — a different axis from the GLP-1 incretins, which is exactly why it pairs with them rather than duplicating them. The flagship combination is CagriSema (cagrilintide + semaglutide), cheap and effective at low doses; it's also paired with retatrutide for two complementary appetite mechanisms.
- Breaks GLP-1 stalls / restores appetite suppression on a tirz base
- Amylin-receptor agonist for satiety; different axis from GLP-1
- Nausea, injection-site reactions, constipation, fatigue
- Too much can be fatiguing
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.